 |
answer text |
<p>The national guidelines advise clinical commissioning groups (CCGs) that local
decisions should be made regarding arrangements for the on-going prescribing of liothyronine,
taking into account the local needs of the population. While CCGs are expected to
have regard to national guidance, they are entitled to develop their own local approaches
to its implementation. During a debate on 20 June on the Branded Health Service Medicines
(Costs) Regulations, I committed to pursuing further with NHS England ways in which
they can clarify the guidelines on the prescribing of liothyronine to CCGs, including
looking at whether greater clarity on the criteria for appropriate patient usage is
merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and
East Surrey Sustainability and Transformation Partnership (STP) clinical board, which
covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens
CCG, following engagement with primary care clinicians and endocrinologists. Based
on the evidence presented, the decision not to routinely prescribe Liothyronine (T3)
was supported across the STP region. It was, however, recognised that there would
be some exceptions to this and that the use of the individual funding request triage
process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
|
|
